SEC Form 4 · accession 0001437749-17-001875
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Wrighton-Smith
Officer — Chief Executive Officer · Director
Period of report
Feb 6, 2017
Accepted (ET)
Feb 7, 2017 · 6:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Feb 6, 2017 | M | 25,000 | $0.81 | A | 463,495 | D | |
| Ordinary SharesF3 | Feb 6, 2017 | S | 25,000 | $13.355 | D | 438,495 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $0.81 | Feb 6, 2017 | M | 25,000 | D | — | Feb 17, 2020 | Ordinary Shares | 25,000 | 76,438 | D |
Explanation of responses
- F1The original exercise price of these options was priced in GBP0.51 and converted to US$ at an exchange rate of US$1.58823=1GBP.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
- F3The price reported for the sales on February 6, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.35 to $13.50 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- F4Exercise from an option granted February 28, 2013, which became fully vested on April 1, 2014.